Tag: AGC Biologics

Manufacturing, Mergers and Acquisitions, Research and Development

AGC Biologics and BioConnection Team Up on Biopharma Drug Development and Manufacturing

May 24, 2024

Via: Biopharm International

On May 22, 2024, AGC Biologics and BioConnection, a contract manufacturing organization specializing in aseptic filling of vials and syringes for clinical and commercial production, announced that they have entered into a new strategic partnership. Under the agreement, the companies […]

Mergers and Acquisitions

Genenta Science, AGC Biologics Enter Development and Manufacturing Service Pact

February 7, 2023

Via: Contract Pharma

Genenta Science, a clinical-stage biotechnology company engaged in the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, has entered into a development and manufacturing service agreement (MSA) with AGC Biologics S.p.A. to manufacture cell therapy lentivirus-based product for […]

Cell and Gene Therapy, Industry

AGC Biologics Supports Altheia Science’s Gene Therapy Programs

July 28, 2022

Via: Contract Pharma

AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), entered a new partnership with Altheia Science, a gene therapy company pioneering cell and gene therapy strategies to treat autoimmune diseases and cancer. Under the alliance,Altheia Science aims to […]

Manufacturing, Research and Development

AGC Biologics Expands pDNA and mRNA Manufacturing Capacity

September 14, 2021

Via: Contract Pharma

AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), unveiled expansion plans for the company’s Heidelberg facility to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects. With this expansion, AGC Biologics is boosting its current […]